Abstract submissions are now open for Small is Beautiful {4ever}, the 4th International Congress on Single Case Designs, taking place in Groningen, The Netherlands, from 21 to 23 April 2027. The congress brings together researchers, clinicians, educators and students from around the world to share the latest developments in single-case experimental and observational designs, personalised research methods and individualised care. Whether you are new to the field or an experien

This paper explores how the Multiphase Optimization STrategy (MOST) can be combined with single-case experimental designs to optimise behavioural interventions, highlighting opportunities to develop more adaptive, personalised, and equitable evidence-based interventions.

Learn when N-of-1 trials require ethics approval and explore the key factors that distinguish routine clinical care from research, including a practical framework to support ethical decision-making.

The International Collaborative Network for N-of-1 Trials and Single-Case Designs (ICN) has submitted a public comment in response to the U.S. Food and Drug Administration’s (FDA) draft guidance, Considerations for the Use of the Plausible Mechanism Framework to Develop Individualized Therapies that Target Specific Genetic Conditions with Known Biological Cause. The draft guidance represents an important step towards recognising that flexible evidentiary approaches are needed

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has launched a public consultation on its proposed Rare Disease Therapies Regulatory Framework. The draft framework aims to introduce a more flexible regulatory pathway for rare disease therapies, recognising that conventional approaches to evidence generation are often not feasible for very small patient populations. These proposals are highly relevant to N-of-1 trials and single-case designs, which have the p

In January 2026, the International Collaborative Network for N-of-1 Trials and Single-Case Designs (ICN) has now grown to more than 800 members across 48 countries, reflecting the increasing global interest in personalised research and healthcare. Since its establishment, the Network has brought together researchers, clinicians and consumers committed to advancing the science and application of N-of-1 trials and single-case designs. Our members represent a broad range of disc

The article titled "Personality psychology is getting personal: Advancing the field through personalization" by Modersitzki, Phan, McDonald, Wright, and Renner explores how the field of psychology can be strengthened by embracing personalisation in its theoretical frameworks, measurement strategies, and methodological designs. The authors argue that traditional psychological research, which focuses primarily on population-level traits and between-person variability, falls sho

In July 2025, ICN welcomed Associate Professor Harriëtte Riese to its Executive Committee, further strengthening the network’s international expertise in personalised longitudinal research and single-case methodologies.

Rare diseases demand new ways of generating evidence. Learn how the Emma Center for Personalized Medicine is using single-case experimental designs and N-of-1 trials to accelerate the development, evaluation and implementation of personalised therapies.

This tutorial introduces paired cycle designs for analysing continuous data in N-of-1 trials, demonstrating how they strengthen within-patient treatment comparisons and support the aggregation of findings across multiple trials.